Literature DB >> 21103857

[Stereotactic radiosurgery and fractionated stereotactic radiotherapy of acoustic neuromas].

F Unger1, K Dominikus, K Haselsberger.   

Abstract

Stereotactic radiosurgery (SRS) is a neurosurgical field that has become increasingly important in the treatment of acoustic neuromas. Radiosurgical treatment modalities include the Gamma knife, the linear accelerator (LINAC), and the CyberKnife. Gamma knife radiosurgery (GKRS) is still unsurpassed in terms of the spatial accuracy of radiation delivery and has been used for decades in acoustic neuromas (>18000 patients). In contrast to surgical resection, the goal of SRS is long-term prevention of tumour growth with preservation of neurological function. Radiation-induced neuropathies rarely occur. However, there are essential differences between SRS and fractionated stereotactic radiotherapy (FSR) in terms of both their radiobiological effects and their modes of application. SRS can be performed in an outpatient setting. Neuromas of up to 3 cm in diameter represent potential candidates for SRS or FSR. For larger tumours, cystic lesions and neuromas with brain stem compression, microsurgical resection in experienced neurosurgical centres is still the preferred option. SRS (and FSR) are possible options for patients with tumour progression after subtotal surgery or tumour recurrence, or for patients unable or unwilling to undergo surgery.

Entities:  

Mesh:

Year:  2011        PMID: 21103857     DOI: 10.1007/s00106-010-2191-x

Source DB:  PubMed          Journal:  HNO        ISSN: 0017-6192            Impact factor:   1.284


  55 in total

Review 1.  Dose selection in stereotactic radiosurgery.

Authors:  J C Flickinger; D Kondziolka; L D Lunsford
Journal:  Neurosurg Clin N Am       Date:  1999-04       Impact factor: 2.509

2.  Acoustic neuroma--the patient's perspective: subjective assessment of symptoms, diagnosis, therapy, and outcome in 541 patients.

Authors:  D A Wiegand; V Fickel
Journal:  Laryngoscope       Date:  1989-02       Impact factor: 3.325

3.  The radiobiology of radiosurgery.

Authors:  D A Larson; J C Flickinger; J S Loeffler
Journal:  Int J Radiat Oncol Biol Phys       Date:  1993-02-15       Impact factor: 7.038

4.  Costs and effects of microsurgery versus radiosurgery in treating acoustic neuroma.

Authors:  L van Roijen; H G Nijs; C J Avezaat; G Karlsson; C Linquist; K H Pauw; F F Rutten
Journal:  Acta Neurochir (Wien)       Date:  1997       Impact factor: 2.216

5.  Volumetrical measurements in vestibular schwannoma, the influence of slice thickness and patient's repositioning.

Authors:  Floriana S Luppino; Edward Grooters; Francisca T de Bruïne; Aeilko H Zwinderman; Andel G L van der Mey
Journal:  Otol Neurotol       Date:  2006-10       Impact factor: 2.311

6.  Hearing preservation in patients with unilateral vestibular schwannoma after gamma knife surgery.

Authors:  Jean Régis; Manabu Tamura; Christine Delsanti; Pierre-Hugues Roche; William Pellet; Jean-Marc Thomassin
Journal:  Prog Neurol Surg       Date:  2008

7.  Tumor-volume changes after radiosurgery for vestibular schwannoma: implications for follow-up MR imaging protocol.

Authors:  O W M Meijer; E J Weijmans; D L Knol; B J Slotman; F Barkhof; W P Vandertop; J A Castelijns
Journal:  AJNR Am J Neuroradiol       Date:  2008-02-22       Impact factor: 3.825

8.  Hearing preservation following fractionated stereotactic radiotherapy for vestibular schwannomas: prognostic implications of cochlear dose.

Authors:  Carys Thomas; Salvatore Di Maio; Roy Ma; Emily Vollans; Christina Chu; Brenda Clark; Richard Lee; Michael McKenzie; Montgomery Martin; Brian Toyota
Journal:  J Neurosurg       Date:  2007-11       Impact factor: 5.115

9.  Gamma knife radiosurgery for vestibular schwannomas.

Authors:  Seiji Fukuoka; Masami Takanashi; Atsufumi Hojyo; Masanori Konishi; Chiharu Tanaka; Hirohiko Nakamura
Journal:  Prog Neurol Surg       Date:  2009

10.  Neurofibromatosis 2, radiosurgery and malignant nervous system tumours.

Authors:  M E Baser; D G Evans; R K Jackler; E Sujansky; A Rubenstein
Journal:  Br J Cancer       Date:  2000-02       Impact factor: 7.640

View more
  5 in total

1.  [Vestibular schwannoma. Part 2: therapy, prognosis, and rehabilitation].

Authors:  W Maier; F Hassepaß; A Aschendorff; R Laszig
Journal:  HNO       Date:  2012-10       Impact factor: 1.284

Review 2.  [Value of different strategies in the treatment of vestibular schwannoma: therapeutic aspects and literature analysis].

Authors:  W Maier; T D Grauvogel; R Laszig; G J Ridder
Journal:  HNO       Date:  2011-05       Impact factor: 1.284

3.  [Schwannoma in the epipharynx: a rare differential diagnosis].

Authors:  M F Meyer; A Anagiotos; J C Lüers; H Löser; E Wardelmann; D Beutner
Journal:  HNO       Date:  2013-05       Impact factor: 1.284

4.  Short-term outcomes of CyberKnife therapy for advanced high-risk tumors: A report of 160 cases.

Authors:  Yi-Shan Wang; Yuan-Yuan Wang; Peng Jiang; Jian-Jun Ma; Zhen Qu; Xi-Lin Wang; Jun-Ti Li; Xi-Feng Jia
Journal:  Exp Ther Med       Date:  2012-01-12       Impact factor: 2.447

5.  Clinical application of CyberKnife for high-risk central nervous system tumors: A clinical trial report of 60 cases.

Authors:  Xin Wang; Yuan-Yuan Wang; Peng Jiang; Jian-Jun Ma; Zhen Qu; Han-Chen Liu; Shan-Shan Wang; Yi-Shan Wang
Journal:  Exp Ther Med       Date:  2011-09-23       Impact factor: 2.447

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.